In his latest essay, Milan Kundera [1] outlines a new character, the 'danseur'. The dancer (or news-courtier) is an ever-present intellectual in the media (newspapers, magazines, radio and especially TV). He is always ready to otfer his valiant comments devoid of doubt on whatever happens in the world. What really matters to the 'danseur' is being on the news and imposing his presence. It rs dilficult not to apply this characterization to the medical field and to miss the similarities between Kundera's 'danseurs' and the prodigal experts who afflict or.rr field [2] . Inevitably sponsored by the pharmaceutical industry, the prodigal experts move from one meeting to the other, providing optimism and con; tinuity (same talk, same slides). In psychiatric terms this translates into a constant disrnissal of psychotherapeutic modalities, that are overshadowed by the pharmacological (at times only pharmaceutical) approach. This is particularly evident in the field of anxiety disorders (e.g., panic), where the superiority of psychotherapeutic tools, both in the short and long terrn 13, 11, is not achieving adequate currency.
In this setting, I year ago, this journal raised the issue as to whether the use of anti-dl depressant drugs in depression might be bene-I ficial in the short term, but worsen the progression of the disease in the long term, by I increasing tfre biochemical vulnerability to depression pnd decreasing its likelihood of subsequent?esponse to pharmacotherapy [5] . The editorial was largely speculative and the clinical and biochernical evidence for this hypothesis was equivocal at best. 11 sparked however a debate that had been until then avoided (or censored?) [6] . Despite a largely critical response from three prominent psychopharmacologists (William Potter, Donald Klein and Robert Post), it was deemed to have raised some legitimate issues [6] . Ross Baldessarini [7] , in this journal, extended these issues to the risks and implications of interrupting maintenance psychotropic drug therapy in bipolar disorder and schizophrenia. Long-tenn exposure to centrally active neuropharmacological agents can induce adaptive physiological changes in the brain [7] , that may include genomic effects in addition to those which they elicit on amine reupHolding On: Depression, Sensitization by Antidepressant Drugs, and the Prodigal Experts ,.r,;' .i 1."+li, take [8] . Abrupt drug removal is associated with a variety of potentially untoward responses, in a complex, multifactorial model encompassing various interlocking processes at the biochemical and experiential levels [7] . Massimo Biondi [9] attempted a psychosomatic synthesis of such processes. He also provided a sound justification for a psychosomatic journal being the ideal forum for this discussion.
The neurobiological framework of sensitization phenomena in depression is provided by the concept of tolerance. Dispositional (pharrnacokinetic) tolerance, which reduces the concentration of a drug or its duration of action, is often confused with functional (pharmacodynamic) processes which change sensitivity to a drug [0] . Continued drug treatment may recruit processes that oppose the initial acute e{Iects ofa drug or ofreceptor alterations. When drug treatment ends, these processes may operate unopposed, at least for some time [10] . Reference to the fine tuning and integration of different serotonin receptors I l] may provide a potential relevance of these processes to the use of antidepressant drugs in depression. Changes in postreceptor signal transduction, in intraneuronal signaling pathways, in neuronal architecture, connections or sensitivity to neurotransnritters, in neurotransmitter syrthesis and distribution are possible [0] . If these changes had to occur, a number of clinical issues would ernerge.
I na p pr o pri at e U s e of At tti d e pre s,s ant Dr u g.r. The effectiveness of antidepressant drugs is established only in major depressive disorders [12] . However, there is a growing tendendy to use them also in the setting of a collection of dysphoric complaints or demoralization. This tendency has been considerably increased by the introduction of the selective serotonin reuptake inhibitors (SSRI), because of their better tolerability compared to the tricyclics.
Carroll [2] warned about the inappropriate use of antidepressant drugs more than a decade ago: '... we strongly suspect that many patients who are sirnply unhappy or dysphoric receive these drugs, with predictable consequences in terms of rnorbidity frour side effects, mortality from overdose, economic waste, and irrational, unproductive clinical management'. To the sarne extent that awareness of tardive dyskinesia has limited inappropriate use of antipsychotics, or antibiotics should not be routinely prescribed with nrinor, viral aihnents, the use of antidepressant drugs below the severity threshold provided by the diagnosis of major depressive disorder may lead to sensitization without any clear benefit. Similar considerations rnay apply to the use of antidepressants in chronic pain.
D e p e nd e nc e v-e rs u s S e ns i t i z a t i orr. The i ssue of dependence has shifted drug treatment of anxiety disorders from use of benzodiazepines to antidepressant drugs. Biondi [9] , for instance, expresses his orientation toward long-term imiprarnine or MAO inhibitor treatment. Once again, let us assume that sensitization by antidepressants exists. Such treatment would increase the vulnerability to depression. A simple way of exploring this research question rvould be to cornpare the long-term incidence of depression in patients randornly assigned to antidepressant drugs or benzodiazepines. Paradoxically, benzodiazepines might be reevaluated. If I had to choose between potential dependence to benzodiazepines and increased vulnerability to depression, I would go for the former.
Full versns Stfttherapeutic Dosage o"f Antidepressants. There is increasing consensus about the advantage of maintaining patients at the acute treatment dosage Il 3] . The rationale for this choice would be the insufllcient protective e{fects of subtherapeutic doses. Keeping a patient on low-dose antidepressants for a long time (a very comrnon practice, Acute versus Proph):lactic Effect oJ-Antidepressants. The full-dose continuation treatment strategies, however, endorse a hidden conceptual model: that what is effective acutely in depression is also the best option for continuation treatment. The stages of development of a disorder would be uninfluential in guiding the treatment. There is evidence, however, to call such views in question [4] . Different stages of illness may require different types of treatment. For instance, drugs that act primarily as 5-HT2 antagonists (such as ritanserin or mianserin) may prove more suitable for continuation treatment. whereas traditionai antidepressants may be more suitable in the acute phase. 5-HT2 antagonists, in fact, may act against the enhanced 5-HT2 receptor function prodromal to onset or relapse of depression [5] .
Fading oJ'Treatment Effects. A loss of antidepressant effect with long-term treatment has been repeatedly observed both in mood [6] and anxiety disorders [17] . Mann [16] , for instance, observed such a phenomenon with MAO inhibitors without loss of MAO inhibition. Probably its best exemplification cornes fion-r the Pittsburgh Maintenance Study [13] . This study is simply viewed, because of the deformation entailed by the quest for statistical significance, as an investigation shorving the superiority of high-dose antidepressant treatment versus other modalities. Ilowever, if one looks at the study carefully, one may discover that about 180/o of patients who initially fully responded to imipramine relapsed while being on full-dose imipramine. Since other patients dropped out, the percentage of patients in the medication clinic and active imiprarnine group who did not relapse was only about 600/0. (Interestingly it was 840/o with the combination of interpersonal psychotherapy and pharmacotherapy.) Would a clinician be satisfied with a strategy that loses I patient out of 5 every 3 years, from a pool that has already been decreased by compliance issues? Why does a previously drugresponsive patient stop being so? I have termed this clinical phenomenon fading (progressive decrease of therapeutic effects refractory to dosage increase, after nonimmediate symptomatic improvement) [18] . Is fading related to sensitization? Whv does it not occur in every patient?
Discontinuation of Antidepressant Drugs. Baldessarini [7] described the risks and implications of interrupting abruptly maintenance drug therapy and the clinical advantages of a gradual decrease. It is astonishing how little we know about very practical issues such as discontinuation of antidepressant drugs. In a planned, controlled discontinuation of antidepressants in 40 depressed patients [14], we did not observe any clear-cut withdrawal reactions [19] . However, most of our patients were on tricyclics and decreases were very slow (25 mg of amitriptyline or its equivalents every other week). We lack good, controlled studies of difl'erent schedules of antidepressant reduction. Similarly, there is insufficient biologic exploration of antidepressant withdrawal [19] . Are antidepressant withdrawal phenomena related to sensitization? Are some drugs more likely than others to induce these, phenomena -for instance SSRI [20] ? What is the relationship between duration of treatment and sensitization? In clinical terms this would translate as follows: how long should we treat patients with antidepressants before sensitization becomes a risk?
Temporary versus I yygygyahlqfggg1;or ModtJications. Withdrawal phenomena are generally viewed as adverse effects occurring within 2-3 weeks from drug discontinuation [19] . A hidden conceptual requirement, however, is the fact that full receptor regulation t-
balance is regained after the acute withdrawal phenomena. Baldessarini [7] suggests that 'several months may be required to become physiologically and psychologically'dry' after stopping such agents as alcohol an"d heroin, and perhaps also benzodiazepines (...), suggesting that such periods may be required to reestablish a pre-drug level of neurophysiological and neuropsychological homeostasis'. As to depression, this would translate into a potentially vulnerable postdrug period (extending over a few months). Some epidemiologic evidence as to relapse wottld be consistent with this view. As a result, together with acute and clinically evident symptoms of withdrawal frorn antidepressant drugs, there might be subtle and subclinical symptoms of subacute withdrawal. In other words, if antidepressant drugs increase vulnerability to depression' this may occnr in a specific phase. This appraisal could pave the way for specihc relapsepreventing strategies. Receptor changes may be irreversible, however, such as in tardive dyskinesia. A prolonged benzodiazepine withdrawal syndrome has been described [21] . Kukopulos et al.l22l observed how treatment by antidepressant drugs may contribute to changes of course from unipolar to bipolar illness, and to increased frequence of cyclicity' They thus deserve credit in raising the issue that antidepressant-induced mania may not sirnply be a temporary and fully reversible phenomenon, but trigger complex biochemical mechanisms of illness deterioration. A case of tricyclic-induced mania in a 60-yearold woman, with a long-standing history of unipolar depression (that was followed by rapid cycling refractory to lithium), illustrates the hormonal irnplications of such mechanisms 1231.
Psychotherapeutic versus Pharmacologic Changes. Biondi [9] emphasized how both acute stressors and psychotherapy can induce biological modifications at the central level and how psychotropic drugs and psychologtcal interventions are probably acting on common neurotransmitter pathlvays. The extent and type of action, however, may be dilferent and from such differences differential therapeutic efforts may ensue. For instance, both exposure and imiprarnine may share tlte sanle neurochemical mechanism in severe cases of panic disorder with agoraphobia [24] . However, what they do not share (the fact that changes are generally long-lasting after exposure and short-lived after irnipramine) may be as important [4] .
Are all or some of these issues rvortby of research attention? The reader may judge for himself or herself. Certainly researchers working along these lines are likely to encounter tremendous difficulties in performing their studies and getting them funded and published. As Klein [6] wisely pointed out:
'The industry is not interested, NIMH is not interested, and the FDA is not interested. Nobody is interested.' Our journal is interested. I hope our readers will be interested as well and support in any possible way this independent journal, at the present time alone in its battle for opening a new research paradigm.
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